

August 19, 2022

Kevin Boyle, Sr.  
Chief Executive Officer  
Alaunos Therapeutics, Inc.  
8030 El Rio Street  
Houston, TX 77054

Therapeutics, Inc.

Statement Filed on Form S-3  
2022

Re: Alaunos

Registration

Filed August 12,

File No. 333-266841

Dear Mr. Boyle:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Hagius at 202-551-7967 with any questions.

Please contact Dillon

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Melinda Lackey